z-logo
open-access-imgOpen Access
FABRICATION, OPTIMIZATION AND EX-VIVO CHARACTERIZATION OF FEBUXOSTAT LOADED NANOSTRUCTURED LIPID CARRIER BY 3 SQUARE FULL FACTORIAL DESIGN
Author(s) -
Umang Varia,
Ritiksha Khatri,
Hitesh Katariya,
Krunal Detholia
Publication year - 2022
Publication title -
journal of advanced scientific research
Language(s) - English
Resource type - Journals
ISSN - 0976-9595
DOI - 10.55218/jasr.202213131
Subject(s) - factorial experiment , zeta potential , particle size , materials science , solid lipid nanoparticle , sonication , ex vivo , chromatography , drug carrier , drug delivery , pulmonary surfactant , chemistry , chemical engineering , nanotechnology , nanoparticle , mathematics , in vitro , biochemistry , statistics , engineering
Nano Structured Lipid Carriers (NLCs) are potential alternative of the tradition colloidal drug carrier. The main benefit is related to the well-known concept that lipids used in nanoparticle formulation promote drug oral absorption because they go through the same physiological mechanism as food lipid digestion. The objective of the present work is to use potential carrier NLCs for the oral delivery of poorly soluble drug Febuxostat (FEB). FEB-NLCs were formulated by High Speed Homogenization with Ultra sonication method using Capmul GMS 50 K as solid lipid and Transcutol HP as a liquid lipid. The 32 full factorial design utilized to study the effect of influence of solid lipid to liquid lipid ratio and concentration of surfactant, on the particle size and entrapment efficiency. Mean particle size and entrapment efficiency were found for all prepared formulation in the range of 196.66±2.08 nm to 368.33±2.51 nm and 74.80±0.52 % to 86.47±0.749 % respectively. Zeta potential was -15.2mv which is negative enough to give good stability. TEM study shows good spherical morphology of particle with diameter less than 200nm. In-vitro and Ex-Vivo study revel that NLCs gives biphasic release of the drug; first initial burst release and then sustained release up to 24 hour. The formulated NLCs dispersion was successfully converted in to the free flowing powder using trehalose as a cryoprotectant. In conclusion, FEB-NLCs potential carrier for the oral delivery and controlled release of drug which may reduce dosing frequency and improve patient compliance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here